|
1
|
Saika K and Sobue T: Cancer statistics in
the world. Gan To Kagaku Ryoho. 40:2475–2480. 2013.(In Japanese).
PubMed/NCBI
|
|
2
|
Arredondo J, Baixauli J, Pastor C,
Chopitea A, Sola JJ, González I, A-Cienfuegos J, Martínez P,
Rodriguez J and Hernández-Lizoain JL: Mid-term oncologic outcome of
a novel approach for locally advanced colon cancer with neoadjuvant
chemotherapy and surgery. Clin Transl Oncol. 19:379–385. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brabletz T, Kalluri R, Nieto MA and
Weinberg RA: EMT in cancer. Nat Rev Cancer. 18:128–134. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Olaussen KA, Dunant A, Fouret P, Brambilla
E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH,
et al: DNA repair by ERCC1 in non-small-cell lung cancer and
cisplatin-based adjuvant chemotherapy. N Engl J Med. 355:983–991.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang J, Chen Y, Xiang F, Li M, Li H, Chi J
and Ren K: Suppression of TGF-β1 enhances chemosensitivity of
cisplatin-resistant lung cancer cells through the inhibition of
drug-resistant proteins. Artif Cells Nanomed Biotechnol.
46:1505–1512. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu Y, Jin D, Wang X, Du J, Di W, An J,
Shao C and Guo J: UBE2C induces cisplatin resistance via
ZEB1/2-dependent upregulation of ABCG2 and ERCC1 in NSCLC cells. J
Oncol. 2019:86078592019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hsu DS, Lan HY, Huang CH, Tai SK, Chang
SY, Tsai TL, Chang CC, Tzeng CH, Wu KJ, Kao JY and Yang MH:
Regulation of excision repair cross-complementation group 1 by
Snail contributes to cisplatin resistance in head and neck cancer.
Clin Cancer Res. 16:4561–4571. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
He S, Carman CV, Lee JH, Lan B, Koehler S,
Atia L, Park CY, Kim JH, Mitchel JA, Park JA, et al: The tumor
suppressor p53 can promote collective cellular migration. PLoS One.
14:e02020652019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Donadel G, Garzelli C, Frank R and
Gabrielli F: Identification of a novel nuclear protein synthesized
in growth-arrested human hepatoblastoma HepG2 cells. Eur J Biochem.
195:723–729. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gabrielli F and Tofanelli S: Molecular and
functional evolution of human DHRS2 and DHRS4 duplicated genes.
Gene. 511:461–469. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bray JE, Marsden BD and Oppermann U: The
human short-chain dehydrogenase/reductase (SDR) superfamily: A
bioinformatics summary. Chem Biol Interact. 178:99–109. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bjorkqvist AM, Wolf M, Nordling S,
Tammilehto L, Knuuttila A, Kere J, Mattson K and Knuutila S:
Deletions at 14q in malignant mesothelioma detected by
microsatellite marker analysis. Br J Cancer. 81:1111–1115. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Debiec-Rychter M, Sciot R, Pauwels P,
Schoenmakers E, Dal Cin P and Hagemeijer A: Molecular cytogenetic
definition of three distinct chromosome arm 14q deletion intervals
in gastrointestinal stromal tumors. Genes Chromosomes Cancer.
32:26–32. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shao JY, Huang XM, Yu XJ, Huang LX, Wu QL,
Xia JC, Wang HY, Feng QS, Ren ZF, Ernberg I, et al: Loss of
heterozygosity and its correlation with clinical outcome and
Epstein-Barr virus infection in nasopharyngeal carcinoma.
Anticancer Res. 21:3021–3029. 2001.PubMed/NCBI
|
|
17
|
Pellegrini S, Censini S, Guidotti S,
Iacopetti P, Rocchi M, Bianchi M, Covacci A and Gabrielli F: A
human short-chain dehydrogenase/reductase gene: Structure,
chromosomal localization, tissue expression and subcellular
localization of its product. Biochim Biophys Acta. 1574:215–222.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Peterson LE, Ozen M, Erdem H, Amini A,
Gomez L, Nelson CC and Ittmann M: Artificial neural network
analysis of DNA microarray-based prostate cancer recurrence.
Proceedings of the IEEE Symposium on Computational Intelligence in
Bioinformatics and Computational Biology. 1–8. 2005.
|
|
19
|
Shedden KA, Taylor JM, Giordano TJ, Kuick
R, Misek DE, Rennert G, Schwartz DR, Gruber SB, Logsdon C, Simeone
D, et al: Accurate molecular classification of human cancers based
on gene expression using a simple classifier with a pathological
tree-based framework. Am J Pathol. 163:1985–1995. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bhattacharyya C, Grate LR, Rizki A,
Radisky D, Molina FJ, Jordan MI, Bissell MJ and Mian IS:
Simultaneous classification and relevant feature identification in
high-dimensional spaces: Application to molecular profiling data.
Signal Processing. 83:729–743. 2003. View Article : Google Scholar
|
|
21
|
Shimonosono M, Idichi T, Seki N, Yamada Y,
Arai T, Arigami T, Sasaki K, Omoto I, Uchikado Y, Kita Y, et al:
Molecular pathogenesis of esophageal squamous cell carcinoma:
Identification of the antitumor effects of miR145-3p on gene
regulation. Int J Oncol. 54:673–688. 2019.PubMed/NCBI
|
|
22
|
Yamada H, Arakawa Y, Saito S, Agawa M,
Kano Y and Horiguchi-Yamada J: Depsipeptide-resistant KU812 cells
show reversible P-glycoprotein expression, hyper-acetylated
histones, and modulated gene expression profile. Leukemia research.
30:723–734. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Han Y, Song C, Wang J, Tang H, Peng Z and
Lu S: HOXA13 contributes to gastric carcinogenesis through DHRS2
interacting with MDM2 and confers 5-FU resistance by a
p53-dependent pathway. Mol Carcinog. 57:722–734. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Deisenroth C, Thorner AR, Enomoto T, Perou
CM and Zhang Y: Mitochondrial Hep27 is a c-Myb target gene that
inhibits Mdm2 and stabilizes p53. Mol Cell Biol. 30:3981–3993.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cunningham D, Atkin W, Lenz HJ, Lynch HT,
Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet.
375:1030–1047. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bowden NA: Nucleotide excision repair: Why
is it not used to predict response to platinum-based chemotherapy?
Cancer Lett. 346:163–171. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Park DJ and Lenz HJ: Determinants of
chemosensitivity in gastric cancer. Curr Opin Pharmacol. 6:337–344.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Selvakumaran M, Pisarcik DA, Bao R, Yeung
AT and Hamilton TC: Enhanced cisplatin cytotoxicity by disturbing
the nucleotide excision repair pathway in ovarian cancer cell
lines. Cancer Res. 63:1311–1316. 2003.PubMed/NCBI
|
|
31
|
Reynolds C, Obasaju C, Schell MJ, Li X,
Zheng Z, Boulware D, Caton JR, Demarco LC, O'Rourke MA, Shaw Wright
G, et al: Randomized phase III trial of gemcitabine-based
chemotherapy with in situ RRM1 and ERCC1 protein levels for
response prediction in non-small-cell lung cancer. J Clin Oncol.
27:5808–5815. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cobo M, Isla D, Massuti B, Montes A,
Sanchez JM, Provencio M, Viñolas N, Paz-Ares L, Lopez-Vivanco G,
Muñoz MA, et al: Customizing cisplatin based on quantitative
excision repair cross-complementing 1 mRNA expression: A phase III
trial in non-small-cell lung cancer. J Clin Oncol. 25:2747–2754.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Simon G, Sharma A, Li X, Hazelton T, Walsh
F, Chiappori CA, Haur E, Tanvetyanon T, Antonia S, Cantor A and
Bepler G: Feasibility and efficacy of molecular analysis-directed
individualized therapy in advanced non-small-cell lung cancer. J
Clin Oncol. 25:2741–2746. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kruiswijk F, Labuschagne CF and Vousden
KH: p53 in survival, death and metabolic health: A lifeguard with a
licence to kill. Nat Rev Mol Cell Biol. 16:393–405. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu YC, Chang PY and Chao CC: CITED2
silencing sensitizes cancer cells to cisplatin by inhibiting p53
trans-activation and chromatin relaxation on the ERCC1 DNA repair
gene. Nucleic Acids Res. 43:10760–10781. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang H, Zhang G, Zhang H, Zhang F, Zhou B,
Ning F, Wang HS, Cai SH and Du J: Acquisition of
epithelial-mesenchymal transition phenotype and cancer stem
cell-like properties in cisplatin-resistant lung cancer cells
through AKT/β-catenin/Snail signaling pathway. Eur J Pharmacol.
723:156–166. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang AD, Fan F, Camp ER, van Buren G, Liu
W, Somcio R, Gray MJ, Cheng H, Hoff PM and Ellis LM: Chronic
oxaliplatin resistance induces epithelial-to-mesenchymal transition
in colorectal cancer cell lines. Clin Cancer Res. 12:4147–4153.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhou Y, Wang L, Ban X, Zeng T, Zhu Y, Li
M, Guan XY and Li Y: DHRS2 inhibits cell growth and motility in
esophageal squamous cell carcinoma. Oncogene. 37:1086–1094. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Quail DF and Joyce JA: Microenvironmental
regulation of tumor progression and metastasis. Nat Med.
19:1423–1437. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhou BP, Deng J, Xia W, Xu J, Li YM,
Gunduz M and Hung MC: Dual regulation of Snail by
GSK-3beta-mediated phosphorylation in control of
epithelial-mesenchymal transition. Nat Cell Biol. 6:931–940. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang SP, Wang WL, Chang YL, Wu CT, Chao
YC, Kao SH, Yuan A, Lin CW, Yang SC, Chan WK, et al: p53 controls
cancer cell invasion by inducing the MDM2-mediated degradation of
Slug. Nat Cell Biol. 11:694–704. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lin TY and Hsu HY: Ling Zhi-8 reduces lung
cancer mobility and metastasis through disruption of focal adhesion
and induction of MDM2-mediated Slug degradation. Cancer Lett.
375:340–348. 2016. View Article : Google Scholar : PubMed/NCBI
|
